ALLOGENEIC BONE MARROW TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCY

我们的研究目标是在以下领域取得进一步进展 异基因移植将导致更好的无病 A)通过降低白血病复发率来提高存活率和治愈率 骨髓移植后；b)减少急性和慢性疾病的发生率 移植物抗宿主病；c)预防巨细胞病毒相关疾病的发展 减少间质性肺炎；以及d)减少 预备养生法。为此，我们提出了五项临床试验。 题为《异基因骨髓移植用于血液学》的项目 恶性“。 我们建议进行一系列第一阶段、第二阶段和第三阶段试验，旨在 提高准备方案的疗效和降低毒副作用 用于接受异基因骨髓移植的患者。在……里面 此外，我们将继续并扩大我们的化学预防试验 相关和非相关骨骼后的急性移植物抗宿主病 骨髓移植。我们还将进行试验，以解决 改善骨髓移植的感染性并发症 应用药物或药物预防巨细胞病毒感染 免疫学方法，我们将探索新的预防方法 骨髓移植后真菌感染的风险。五个中的四个 具体目标将在国家希望之城联合实施 医学中心和斯坦福大学。过去，这两个人 各机构在临床试验方面密切合作，这些试验已经 取得了令人振奋的结果。需要检验的假设是， 本建议中描述的方案可能会产生更好的结果 通过其他广泛使用的方法获得的，并将增加 治疗的安全性。我们已经提出了前瞻性试验，以确定 新方案在治疗白血病和预防移植物抗白血病中的作用 宿主疾病和感染是从研究中发展而来的 由本计划项目拨款的调查人员提供。

The goal of our studies is to achieve further progress in the areas of allogeneic transplantation which would result in improved disease free survival and cure rates by a) Decreasing the leukemia relapse rate following marrow grafting; b) Reducing the incidence of acute and chronic graft-versus-host disease; c) Preventing the development of CMV associated interstitial pneumonia; and d) Decreasing the complications of the preparatory regimen. To this end we propose five clinical trials in this project entitled "Allogeneic Bone Marrow Transplantation for Hematologic Malignancy". We propose to conduct a series of Phase I, II and III trials designed to improve the efficacy and reduce the toxicity of the preparatory regimen used for patients undergoing allogeneic marrow transplantation. In addition, we will continue and extend our trials in the chemoprophylaxis of acute graft-versus-host disease after both related and unrelated bone marrow transplantation. We will also conduct trials to address the infectious complications of marrow transplantation by improving the prophylaxis of cytomegalovirus infection utilizing either pharmacologic or immunologic methods and we will explore novel approaches to the prevention of fungus infection after marrow transplantation. Four of the five specific aims will be carried out jointly at the City of Hope National Medical Center and at Stanford University. In the past, these two institutions have collaborated closely in clinical trials which have yielded promising results. The hypothesis to be tested is that the regimens described in this proposal may lead to results which are superior to those obtained with other widely utilized approaches and will increase the safety of the therapy. We have proposed prospective trials to define the role of new regimens used to ablate leukemia and prevent graft-versus- host disease and infection that have been developed from research performed by the investigators in this Program Project Grant.